Xalud Therapeutics, Inc.

Xalud Therapeutics, Inc. is a biotechnology company focused on developing innovative non-viral gene therapies to treat chronic inflammatory conditions by modulating the immune system. Founded in 2009 and headquartered in New York, US, Xalud Therapeutics specializes in gene therapy for chronic inflammatory diseases. The company has raised USD 18.

17 mn through its most recent funding round on May 18, 2021, led by PBM Capital Group. Xalud has successfully completed 3 deals to date, with its lead candidate being XT-150. Xalud Therapeutics specializes in a non-viral plasmid DNA (pDNA)-delivered gene therapy platform, primarily focusing on treating chronic inflammatory conditions through the modulation of the immune system. Their flagship product, XT-150, is a locally injectable gene therapy that expresses a modified version of interleukin-10 (IL-10v), which functions as a potent anti-inflammatory cytokine targeting the root causes of inflammation.

This innovative approach aims to restore homeostasis in the immune system, addressing various chronic inflammatory diseases, particularly in musculoskeletal and neurodegenerative indications. Xalud's technology is developed for a wide array of patients suffering from conditions such as osteoarthritis, multiple sclerosis, and neuropathic pain, expanding its potential client base significantly. The company's products are primarily targeted towards healthcare providers and institutions in the United States, with indications of future expansion into other major markets as their research progresses. Xalud Therapeutics operates through a business model focused on clinical trials and the development of gene therapies, predominantly generating revenue through partnerships and collaborations with research institutions and pharmaceutical companies.

The company engages in B2B transactions, working closely with healthcare providers and clinical research organizations to facilitate the distribution and administration of its gene therapy products. The primary revenue stream derives from successful clinical trial completions and subsequent product approvals, leading to potential licensing agreements and collaborations that enhance market access. Given the nature of the biotechnology sector, revenue generation may also include milestone payments associated with developmental progress and regulatory approvals related to its lead candidate, XT-150, as well as other pipeline projects. In May 2021, Xalud Therapeutics, Inc.

raised USD 18. 17 mn in Series C funding, which will be utilized to support the expansion of its clinical development and non-viral gene therapy platform targeting multiple chronic inflammatory diseases. The company plans to launch new products targeting chronic inflammatory conditions, while also aiming for geographical expansion into more major markets beyond the US as its research advances. The funding from the Series C round is crucial for accelerating these initiatives.